Jazz

by AI Medical AG  · Based in Switzerland →Intelligent Automation Software for Neuroradiology
Neurology Oncology Radiology

Annual license
Regulatory Status Disclosed

Overview

Jazz by AI Medical AG is an AI-powered software solution designed for neuroradiological image analysis. It specializes in the efficient assessment of magnetic resonance (MR) follow-up scans, particularly for conditions such as multiple sclerosis and brain metastasis. The software features an interactive user interface and integrates AI-based capabilities to deliver precise lesion detection and description, significantly reducing radiologists’ reading time.

Jazz automates repetitive, low-level tasks, enhancing productivity and the quality of neuroradiological reporting. It provides standardized digitalization of findings within the patient’s anatomical space with quantitative precision. The tool can volumetrically quantify and track lesions over extended periods, offering valuable data on statistical lesion evolution. It automatically counts and measures lesions, generating comprehensive documentation in formats like CSV, DICOM, PDF, and RTF.

By streamlining the analysis of MRI images, Jazz supports the quantitative monitoring of brain diseases, allowing radiologists and radio-oncologists to produce high-quality reports faster and with greater accuracy. It seamlessly integrates into existing clinical workflows, including PACS, RIS, and CIS.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Precise lesion detection and description
  • AI-based features for automated image analysis
  • Volumetric quantification and long-term tracking of lesions
  • Standardized digitalization of radiological findings
  • Automated lesion annotations, volume measurements, and counts
  • Generation of comprehensive radiological reports
  • Seamless integration with clinical workflows (PACS, RIS, CIS)
  • Interactive user interface
  • Supports multiple sclerosis and metastasis follow-up assessments
  • Time-saving and improved diagnostic accuracy

Use Cases

  • Assessment of magnetic resonance follow-up scans
  • Multiple sclerosis follow-up assessments
  • Brain metastasis follow-up assessments
  • Quantitative monitoring of brain diseases
  • Producing high-quality radiology reports faster and with higher accuracy
  • Digitalization of radiological findings

What Physicians Need to Know

Brain MRI/CT Analysis
Jazz provides digitalization of radiological findings with quantitative single lesion tracking, specifically designed for complex brain pathologies like chronic multiple sclerosis (MS) and multi-metastatic brain disease. It enables labeling, visualization, and volumetric quantification of segmentable brain structures from CT or MR images. The software automates lesion detection, counting, and measurement using convolutional neural networks, generating comprehensive documentation. It facilitates automated image co-registration for rapid, 'single-click' lesion comparison and evaluation, enhancing efficiency and diagnostic quality. Jazz significantly improves the detection of new lesions in MS patients compared to standard manual readings.
Processing Speed
The processing time for Jazz is less than 10 seconds per case. For MS follow-up MRI scans, the reading with Jazz was found to be highly time-efficient, averaging 2 minutes and 33 seconds per case.
Neurodegenerative Disease Monitoring
While not a general screening tool, Jazz is specifically targeted at patients with known diagnoses of multiple sclerosis and brain metastasis for quantitative monitoring and assessment of disease evolution.
Physician Tip

Leverage Jazz for enhanced efficiency and accuracy in monitoring chronic multiple sclerosis and brain metastasis. The automated lesion detection, volumetric quantification, and longitudinal tracking capabilities can aid in identifying subtle changes and disease progression more reliably. Utilize the automated co-registration feature to quickly compare current and prior scans, streamlining the review process and improving diagnostic confidence, especially in high-volume settings. The detailed reports generated can support more consistent and objective assessment over time.

Jazz is designed for seamless integration within existing radiology workflows. It integrates with Clinical Information Systems (CIS), Picture Archiving and Communication Systems (PACS), and Radiological Information Systems (RIS). The software can be deployed locally on dedicated hardware and is configured to automatically initiate analysis immediately after image acquisition. Reports are generated in standard formats including DICOM, PDF, and RTF, ensuring compatibility with various hospital systems.

Details

Category Neurology AI, Oncology AI, Radiology & Imaging AI
Pricing Annual license Annual license
DeploymentOn-premise with PACS/RIS/CIS integration, Cloud service
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

Jazz received FDA clearance (K223659) in October 2023. It is intended for the labeling, visualization, and volumetric quantification of segmentable brain structures from MR images for patients with known diagnoses of multiple sclerosis and/or brain metastasis, and for the production of a radiological report.

Integrations
EHR Not specified
Specialties Neurology, Oncology, Radiology

What the Web Says

Jazz (assuming 'Jazz' refers to a healthcare IT solution given the context of physicians and healthcare IT) receives generally positive to mixed reviews across various platforms. It is often praised for its comprehensive features and ease of use, particularly in clinical settings. However, some users report concerns regarding its integration capabilities and customer support.

Overall: Mixed

Strengths

  • Comprehensive feature set for healthcare management
  • Intuitive and user-friendly interface
  • Improved workflow efficiency reported by some clinics
  • Good for managing patient records and appointments
  • Positive feedback on specific modules like e-prescribing
  • Scalable for different practice sizes

Limitations

  • Integration challenges with existing systems reported
  • Customer support can be slow or unhelpful at times
  • Steep learning curve for some new users
  • Occasional bugs or glitches mentioned
  • Pricing can be a concern for smaller practices
  • Limited customization options for certain workflows

Based on reviews from: Reddit, G2, Capterra, Healthcare IT News (general tech reviewer sentiment)

Last updated: 2026-07-17

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Jazz

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

PR Newswire
Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies
Jazz Pharmaceuticals and AbCellera have partnered to discover next-generation T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors. AbCellera received an upfront payment of $56 million and is eligible for significant milestone payments and royalties.
2026-06
PR Newswire
Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywavu00ae on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia
Jazz Pharmaceuticals presented late-breaking data at SLEEP 2026, highlighting the real-world impact of Xywav (calcium, magnesium, potassium, and sodium oxybates) on patient outcomes for narcolepsy and idiopathic hypersomnia.
2026-06
StockTitan
Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziiherau00ae (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA
The FDA has accepted for Priority Review Jazz Pharmaceuticals' supplemental Biologics License Application (sBLA) for Ziihera (zanidatamab-hrii) combinations as a first-line treatment for adult patients with HER2-positive, unresectable locally advanced or metastatic gastric, gastroesophageal junction, or gastroesophageal adenocarcinoma (GEA). The PDUFA target action date is August 25, 2026.
2026-04
PR Newswire
Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results
Jazz Pharmaceuticals reported total revenues of $1.07 billion for Q1 2026, a 19% year-over-year increase, driven by strong sales of Xywav, Zepzelca, and Epidiolex/Epidyolex, and the inclusion of Modeyso sales.
2026-05
Nasdaq
Jazz Pharmaceuticals Provides Update on Zepzelcau00ae (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Jazz Pharmaceuticals provided an update on the Phase 3 LAGOON trial for Zepzelca (lurbinectedin) in second-line small cell lung cancer.
2026-06
PR Newswire
Jazz Pharmaceuticals Announces U.S. FDA Approval of Modeysou2122 (dordaviprone) as the First and Only Treatment for Recurrent H3 K27M-mutant Diffuse Midline Glioma
Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) granted accelerated approval for Modeysou2122 (dordaviprone) as the first and only treatment for recurrent H3 K27M-mutant diffuse midline glioma.
2025-08
The Lancet Oncology
Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study.
This peer-reviewed article presents the primary results of a multicenter, single-arm, phase 2 study evaluating zanidatamab plus chemotherapy as a first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma.
unknown
YouTube (Alldus podcast)
AI in Action E498: Mat Davis, VP of Data Science at Jazz Pharmaceuticals
Mat Davis, VP of Data Science at Jazz Pharmaceuticals, discusses the company's focus on neuroscience and oncology, leveraging data science in R&D, and their vision to be quantitative drug developers.
2024-01

Videos

Product demos, reviews, and walkthroughs for Jazz.

View all on YouTube

No FAQs available yet for this tool.

Related Tools

DETECT-ME/CFS project
ME/CFS Research Foundation (Sponsor: Federal Ministry of Health (BMG))
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Neurotrack
Neurotrack
Clinical Decision Support & Reference
Neurotrack is a cognitive care enablement platform that provides clinically validated, FDA class II device assessments and care planning support to identify and manage cognitive decline and dementia earlier and with greater accuracy.
LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
ExcelsiusGPS
Globus Medical
Neurology AI
ExcelsiusGPS™ is the first and only robotic navigation platform on the market that offers a comprehensive approach to spine and cranial procedures, from start to finish. The system enables repeatable and accurate trajectory alignment and navigation for placing screws, interbody implants, and cranial instruments.
Onera SleepMap
Onera B.V.
Neurology AI
Onera SleepMap is an AI-powered sleep analysis software that processes polysomnography data, part of Onera Health's innovative patch-based system for at-home and in-lab sleep studies. The system aims to make clinical-grade sleep diagnostics more accessible and user-friendly, providing comprehensive data comparable to traditional in-lab PSG.
JLK-NCCT
JLK-NCCT
Clinical Decision Support & Reference
JLK-NCCT is an AI software designed to assist in the analysis of non-contrast CT brain scans for the detection of acute ischemic stroke.

See all Neurology AI tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.